

Enrico Carmina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1118552/publications.pdf>

Version: 2024-02-01

90
papers

13,374
citations

57752

44
h-index

56717

83
g-index

92
all docs

92
docs citations

92
times ranked

7493
citing authors

#	ARTICLE	IF	CITATIONS
1	Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4237-4245.	3.6	1,811
2	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. <i>Fertility and Sterility</i> , 2009, 91, 456-488.	1.0	1,639
3	Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. <i>Fertility and Sterility</i> , 2012, 97, 28-38.e25.	1.0	1,494
4	Polycystic ovary syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16057.	30.5	1,004
5	Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2038-2049.	3.6	831
6	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1897-1899.	3.6	417
7	Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 167, 1807-1812.	1.3	399
8	Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. <i>Human Reproduction Update</i> , 2014, 20, 334-352.	10.8	389
9	American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1. <i>Endocrine Practice</i> , 2015, 21, 1291-1300.	2.1	387
10	Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred because of Clinical Hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2-6.	3.6	358
11	Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. <i>Fertility and Sterility</i> , 2011, 95, 1073-1079.e11.	1.0	317
12	Abdominal Fat Quantity and Distribution in Women with Polycystic Ovary Syndrome and Extent of Its Relation to Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2500-2505.	3.6	275
13	Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2004, 82, 661-665.	1.0	225
14	The diagnosis of polycystic ovary syndrome in adolescents. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 201.e1-201.e5.	1.3	205
15	Idiopathic Hirsutism*. <i>Endocrine Reviews</i> , 2000, 21, 347-362.	20.1	195
16	21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter study. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 183, 1468-1474.	1.3	163
17	Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. <i>Human Reproduction</i> , 2003, 18, 2289-2293.	0.9	163
18	Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. <i>Fertility and Sterility</i> , 2010, 94, 2197-2201.	1.0	143

#	ARTICLE	IF	CITATIONS
19	DHEA, DHEAS and PCOS. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 213-225.	2.5	138
20	Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. <i>Human Reproduction Update</i> , 2017, 23, 580-599.	10.8	136
21	Treatment of hyperandrogenic alopecia in women. <i>Fertility and Sterility</i> , 2003, 79, 91-95.	1.0	115
22	Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 186-189.	3.6	105
23	Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4629-4638.	3.6	105
24	A 20-Year Follow-up of Young Women With Polycystic Ovary Syndrome. <i>Obstetrics and Gynecology</i> , 2012, 119, 263-269.	2.4	101
25	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1897-1899.	3.6	94
26	Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. <i>Fertility and Sterility</i> , 2005, 84, 413-419.	1.0	91
27	Do hyperandrogenic women with normal menses have polycystic ovary syndrome?. <i>Fertility and Sterility</i> , 1999, 71, 319-322.	1.0	90
28	Polycystic ovaries in hirsute women with normal menses. <i>American Journal of Medicine</i> , 2001, 111, 602-606.	1.5	90
29	Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2006, 86, S7-S8.	1.0	84
30	Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2009, 91, 1332-1335.	1.0	84
31	Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. <i>Minerva Ginecologica</i> , 2004, 56, 1-6.	0.8	76
32	Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2875-2891.	3.6	67
33	Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2008, 89, 642-648.	1.0	66
34	Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?. <i>Fertility and Sterility</i> , 1991, 56, 635-640.	1.0	64
35	A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. <i>Clinical Endocrinology</i> , 2002, 57, 231-234.	2.4	63
36	Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 35-41.	3.3	61

#	ARTICLE	IF	CITATIONS
37	Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 23.	3.3	61
38	Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. <i>Gynecological Endocrinology</i> , 2020, 36, 12-23.	1.7	58
39	Not all women diagnosed with PCOS share the same cardiovascular risk profiles. <i>Fertility and Sterility</i> , 2010, 94, 826-832.	1.0	56
40	Obesity, Adipokines and Metabolic Syndrome in Polycystic Ovary Syndrome. <i>Frontiers of Hormone Research</i> , 2013, 40, 40-50.	1.0	51
41	Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 111-116.	3.3	50
42	Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. <i>Metabolism: Clinical and Experimental</i> , 2017, 73, 22-35.	3.4	50
43	Genetic and environmental aspect of polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 1151-1159.	3.3	48
44	Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major. <i>Calcified Tissue International</i> , 2003, 74, 68-71.	3.1	46
45	Is 11 β -hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate?. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 165, 1837-1842.	1.3	45
46	The ratio of androstenedione: 11 β -hydroxyandrostenedione is an important marker of adrenal androgen excess in women. <i>Fertility and Sterility</i> , 1992, 58, 148-152.	1.0	44
47	Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. <i>Obstetrics and Gynecology</i> , 1995, 85, 971-976.	2.4	44
48	Ovarian and Adrenal Hyperandrogenism. <i>Annals of the New York Academy of Sciences</i> , 2006, 1092, 130-137.	3.8	44
49	Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Fertility and Sterility</i> , 1994, 62, 738-743.	1.0	41
50	The spectrum of androgen excess disorders. <i>Fertility and Sterility</i> , 2006, 85, 1582-1585.	1.0	40
51	Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients. <i>Journal of Endocrinological Investigation</i> , 1986, 9, 5-9.	3.3	36
52	Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women. <i>Fertility and Sterility</i> , 1991, 55, 872-876.	1.0	34
53	Metabolic syndrome in polycystic ovary syndrome. <i>Minerva Ginecologica</i> , 2006, 58, 109-114.	0.8	34
54	The Addition of Dexamethasone to Antiandrogen Therapy for Hirsutism Prolongs the Duration of Remission. <i>Fertility and Sterility</i> , 1998, 69, 1075-1079.	1.0	32

#	ARTICLE	IF	CITATIONS
55	Androgens and Hypertension in Men and Women: a Unifying View. <i>Current Hypertension Reports</i> , 2017, 19, 44.	3.5	32
56	Mild androgen phenotypes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2006, 20, 207-220.	4.7	27
57	Does metformin induce ovulation in normoandrogenic anovulatory women?. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1580-1584.	1.3	26
58	Alterations in androgen conjugate levels in women and men with alopecia. <i>Fertility and Sterility</i> , 1994, 62, 744-750.	1.0	24
59	Anti-androgens for the treatment of hirsutism. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 357-363.	4.1	23
60	Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?. <i>Journal of Women's Health</i> , 2018, 27, 1385-1388.	3.3	23
61	Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systematic review and meta-analysis. <i>Gynecological Endocrinology</i> , 2021, 37, 392-405.	1.7	23
62	Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac003.	0.2	23
63	Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women. <i>Fertility and Sterility</i> , 1990, 54, 245-250.	1.0	21
64	Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?. <i>Fertility and Sterility</i> , 2012, 98, 1043-1046.	1.0	21
65	Ovarian volume in normal and hyperandrogenic adolescent women. <i>Fertility and Sterility</i> , 2015, 104, 196-199.	1.0	20
66	Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 422-426.	3.3	19
67	Increased anti-Müllerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of the link between polycystic ovary syndrome and functional hypothalamic amenorrhea. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 714.e1-714.e6.	1.3	19
68	Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. <i>Clinical Endocrinology</i> , 2019, 91, 553-560.	2.4	19
69	Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency. <i>Fertility and Sterility</i> , 1990, 54, 79-83.	1.0	17
70	PCOS: metabolic impact and long-term management. <i>Minerva Ginecologica</i> , 2012, 64, 501-5.	0.8	17
71	Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual function. <i>Gynecological Endocrinology</i> , 2018, 34, 301-304.	1.7	16
72	A Risk-Benefit Assessment of Pharmacological Therapies for Hirsutism. <i>Drug Safety</i> , 2001, 24, 267-276.	3.2	14

#	ARTICLE	IF	CITATIONS
73	Does ovarian blood flow distinguish between ovulatory and anovulatory patients with polycystic ovary syndrome?. American Journal of Obstetrics and Gynecology, 2003, 189, 1283-1286.	1.3	14
74	Polycystic ovary syndrome: Metabolic consequences and long-term management. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 23-26.	1.2	14
75	High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms. Fertility and Sterility, 2010, 94, 194-197.	1.0	13
76	Need for liver evaluation in polycystic ovary syndrome. Journal of Hepatology, 2007, 47, 313-315.	3.7	12
77	Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research, 2019, 51, 22-34.	1.5	12
78	Reproductive System Outcome Among Patients with Polycystic Ovarian Syndrome. Endocrinology and Metabolism Clinics of North America, 2015, 44, 787-797.	3.2	11
79	Laboratory Assessment. , 2014, , 822-850.e3.		10
80	Evaluation of Hormonal Status. , 2019, , 887-915.e4.		8
81	Topical Eflornithine. American Journal of Clinical Dermatology, 2001, 2, 202.	6.7	7
82	Cutaneous manifestations of polycystic ovary syndrome. Current Opinion in Endocrine and Metabolic Research, 2020, 12, 49-52.	1.4	7
83	Evaluation of Hormonal Status. , 2009, , 801-823.		6
84	Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome. Journal of Endocrinological Investigation, 1998, 21, 580-588.	3.3	5
85	Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis. Diabetology and Metabolic Syndrome, 2021, 13, 18.	2.7	5
86	Hirsutism: investigation and management. Expert Review of Endocrinology and Metabolism, 2010, 5, 189-195.	2.4	4
87	PCOS Phenotypes: Impact on Fertility. , 2018, , 81-87.		1
88	When Periods Stop: Long-Term Consequences of PCOS. , 2009, , 265-270.		1
89	Variations in the Expression of the Polycystic Ovary Syndrome Phenotype. , 2008, , 123-132.		0
90	Polycystic ovary syndrome: an update on diagnostic evaluation. Journal of the Indian Medical Association, 2006, 104, 439-40, 442, 444.	0.2	0